Investing

Crinetics Pharmaceuticals : CRNX

CRNX

Stock Data

$36.18

$0.27 (0.75%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Crinetics Pharmaceuticals Inc is a pioneering clinical-stage pharmaceutical company based in San Diego, California, dedicated to crafting innovative treatments for rare endocrine diseases and endocrine-related tumors. With a focus on oral, nonpeptide therapies, its flagship product, paltusotine, is advancing through clinical trials targeting conditions like acromegaly and carcinoid syndrome. Additionally, Crinetics is exploring treatments for diseases caused by excess ACTH, primary hyperparathyroidism, and other endocrine disorders, aiming to address unmet medical needs with novel therapeutics.

All Crinetics Pharmaceuticals Articles

1 Article

Trey Thoelcke | 2 minutes ago

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

Big pharma is hunting again, and patent cliffs are forcing buyers to overpay or miss out. Three mid-cap biotechs have…